AstraZeneca’s experimental drug may bring serious competition to Plavix – AstraZeneca‘s new pill Brilinta for preventing heart attacks works better than Plavix, the world’s second biggest selling drug, without increasing the amount of life-threatening bleeding, researchers said on Sunday…more
B-I‘s new drug Praxada poised to finally provide an alternative to warfarin – Patients at risk of stroke due to an erratic heartbeat should soon have a viable alternative to 50-year-old warfarin, after a new pill from Boehringer Ingelheim beat expectations in a major clinical study…more Plus, new B-I drug for COPD is looking promising.
Encouraging results for Angiomax in cardiac mortality/survival study – The Medicines Company today announced the publication of one-year results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack and received angioplasty were significantly less likely to suffer cardiac death and had significantly better overall survival if treated with Angiomax (bivalirudin) compared with those treated with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI)…more
FDA to Allos: not so sure about your lymphoma data – Food and Drug Administration reviewers, in a summary prepared for an advisory panel, said their two issues with Allos’ application were “the clinical significance of tumor response and duration of response” as well as “whether the benefit:risk ratio is favorable” for Folotyn…more
Technology. Learning Management Systems. On-line assessment. eMarketing. Social Media. If you’re looking for expertise, and/or for vendor connections in the technology sphere, Impactiviti can help. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!
JUST FOR FUN
Turn up your speakers, sit back for a minute or two, and just enjoy this remarkable video. Rain.
On a personal note: Next week one of my sons joins the Marines. Some thoughts from a proud Dad.
Subscribe to the Impactiviti blog via e-mail
Connect with Steve Woodruff